Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Retinoblastoma: early-phase trial registry
7 of 16 indexed Retinoblastoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 7 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Retinoblastoma: 16 US clinical trials tracked, 7 recruiting.
Retinoblastoma is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition retinoblastoma
OPEN 7 | RECR 44% | LATE 0 | EARLY 10 | RANK #1060 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Distress Syndrome (44% recruiting · 32 trials)
Retinoblastoma lists 7 open slots (44% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Retinoblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Retinoblastoma is recruiting below its size-band peers.
7 of 16 indexed trials (43.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Retinoblastoma research.
Memorial Sloan Kettering Cancer Center accounts for 4 of 16 trials (25%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Retinoblastoma trials plan to enrol fewer than 100 people.
Median target enrolment is 68 among the 16 trials that report a genuine target (sentinel values excluded). 10 of those (62.5%) plan for fewer than 100 participants.
-
Retinoblastoma splits between interventional and observational designs.
10 interventional and 6 observational studies make up this index (62.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
National Cancer Institute (NCI)
NCT01109394
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
Vanderbilt-Ingram Cancer Center
NCT03932786
RB Liquid Biopsy Biorepository
Children's Hospital Los Angeles
NCT04959097
Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.
University of Washington
NCT06725173
Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients
Memorial Sloan Kettering Cancer Center
NCT03546387
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
Stephan Grupp MD PhD
NCT05650749
Retinoblastoma Phase II Expanded Access Clinical Trial
Targeted Therapy Technologies
NCT06679634
Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life
Memorial Sloan Kettering Cancer Center
NCT00639301
Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
St. Jude Children's Research Hospital
NCT01783535
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT04483778
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT03618381
Chemotherapy in Treating Patients With Retinoblastoma
Memorial Sloan Kettering Cancer Center
NCT00002675
Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma
Ann & Robert H Lurie Children's Hospital of Chicago
NCT00179920
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
Pediatric Brain Tumor Consortium
NCT00006246
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00024258
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
Emory University
NCT01331135
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Retinoblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Retinoblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Retinoblastoma page
16 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Retinoblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Retinoblastoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Retinoblastoma condition card totals 16 registered trials; most-linked intervention carboplatin; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.